Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: Results from three randomized, placebo- controlled studies of the combination of acetaminophen, aspirin, and caffeine

J. Goldstein, H. D. Hoffman, J. J. Armellino, J. P. Battikha, S. W. Hamelsky, J. Couch, H. Blumenthal, Richard B. Lipton

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: To examine the benefits of acetaminophen, aspirin, and caffeine (AAC) in the treatment of severe, disabling migraine attacks, in a population of migraine sufferers for whom over-the-counter (OTC) medications are appropriate. Background: Subjects (n=1220) who met the International Headache Society criteria for migraine with or without aura were included in three independent clinical studies. Design/Methods: Post-hoc analysis of 172 subjects who met the criteria for severe, disabling migraine reported a history of migraine attacks characterized by at least severe pain and severe disability, and treated attacks with severe pain and at least severe disability. Subjects who usually vomited with 20% or more of their migraine attacks, and those with incapacitating disability (subjects who required bed rest for more than 50% of their attacks) were not eligible for enrollment. Results: From 1 h and continuing through 6 h postdose, the proportion of responders was significantly greater (p≤0.01) for AAC than placebo. The pain intensity difference from baseline was significantly greater (p≤0.05) for AAC than placebo from 0.5 h through 6 h. The proportion of subjects reporting improvement in functional disability, photophobia, and phonophobia was significantly greater for AAC than placebo from 2 h through 6 h postdose. Conclusions: The nonprescription combination of AAC was well tolerated and effective.

Original languageEnglish (US)
Pages (from-to)684-691
Number of pages8
JournalCephalalgia
Volume19
Issue number7
DOIs
StatePublished - 1999

Fingerprint

Migraine Disorders
Placebos
Population
Pain
Hyperacusis
Migraine without Aura
Therapeutics
Migraine with Aura
Photophobia
Bed Rest
Headache
acetaminophen, aspirin, caffeine drug combination

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers : Results from three randomized, placebo- controlled studies of the combination of acetaminophen, aspirin, and caffeine. / Goldstein, J.; Hoffman, H. D.; Armellino, J. J.; Battikha, J. P.; Hamelsky, S. W.; Couch, J.; Blumenthal, H.; Lipton, Richard B.

In: Cephalalgia, Vol. 19, No. 7, 1999, p. 684-691.

Research output: Contribution to journalArticle

@article{2ac98117dbdb4563bf51d05fd52c6c34,
title = "Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: Results from three randomized, placebo- controlled studies of the combination of acetaminophen, aspirin, and caffeine",
abstract = "Objective: To examine the benefits of acetaminophen, aspirin, and caffeine (AAC) in the treatment of severe, disabling migraine attacks, in a population of migraine sufferers for whom over-the-counter (OTC) medications are appropriate. Background: Subjects (n=1220) who met the International Headache Society criteria for migraine with or without aura were included in three independent clinical studies. Design/Methods: Post-hoc analysis of 172 subjects who met the criteria for severe, disabling migraine reported a history of migraine attacks characterized by at least severe pain and severe disability, and treated attacks with severe pain and at least severe disability. Subjects who usually vomited with 20{\%} or more of their migraine attacks, and those with incapacitating disability (subjects who required bed rest for more than 50{\%} of their attacks) were not eligible for enrollment. Results: From 1 h and continuing through 6 h postdose, the proportion of responders was significantly greater (p≤0.01) for AAC than placebo. The pain intensity difference from baseline was significantly greater (p≤0.05) for AAC than placebo from 0.5 h through 6 h. The proportion of subjects reporting improvement in functional disability, photophobia, and phonophobia was significantly greater for AAC than placebo from 2 h through 6 h postdose. Conclusions: The nonprescription combination of AAC was well tolerated and effective.",
author = "J. Goldstein and Hoffman, {H. D.} and Armellino, {J. J.} and Battikha, {J. P.} and Hamelsky, {S. W.} and J. Couch and H. Blumenthal and Lipton, {Richard B.}",
year = "1999",
doi = "10.1046/j.1468-2982.1999.019007684.x",
language = "English (US)",
volume = "19",
pages = "684--691",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers

T2 - Results from three randomized, placebo- controlled studies of the combination of acetaminophen, aspirin, and caffeine

AU - Goldstein, J.

AU - Hoffman, H. D.

AU - Armellino, J. J.

AU - Battikha, J. P.

AU - Hamelsky, S. W.

AU - Couch, J.

AU - Blumenthal, H.

AU - Lipton, Richard B.

PY - 1999

Y1 - 1999

N2 - Objective: To examine the benefits of acetaminophen, aspirin, and caffeine (AAC) in the treatment of severe, disabling migraine attacks, in a population of migraine sufferers for whom over-the-counter (OTC) medications are appropriate. Background: Subjects (n=1220) who met the International Headache Society criteria for migraine with or without aura were included in three independent clinical studies. Design/Methods: Post-hoc analysis of 172 subjects who met the criteria for severe, disabling migraine reported a history of migraine attacks characterized by at least severe pain and severe disability, and treated attacks with severe pain and at least severe disability. Subjects who usually vomited with 20% or more of their migraine attacks, and those with incapacitating disability (subjects who required bed rest for more than 50% of their attacks) were not eligible for enrollment. Results: From 1 h and continuing through 6 h postdose, the proportion of responders was significantly greater (p≤0.01) for AAC than placebo. The pain intensity difference from baseline was significantly greater (p≤0.05) for AAC than placebo from 0.5 h through 6 h. The proportion of subjects reporting improvement in functional disability, photophobia, and phonophobia was significantly greater for AAC than placebo from 2 h through 6 h postdose. Conclusions: The nonprescription combination of AAC was well tolerated and effective.

AB - Objective: To examine the benefits of acetaminophen, aspirin, and caffeine (AAC) in the treatment of severe, disabling migraine attacks, in a population of migraine sufferers for whom over-the-counter (OTC) medications are appropriate. Background: Subjects (n=1220) who met the International Headache Society criteria for migraine with or without aura were included in three independent clinical studies. Design/Methods: Post-hoc analysis of 172 subjects who met the criteria for severe, disabling migraine reported a history of migraine attacks characterized by at least severe pain and severe disability, and treated attacks with severe pain and at least severe disability. Subjects who usually vomited with 20% or more of their migraine attacks, and those with incapacitating disability (subjects who required bed rest for more than 50% of their attacks) were not eligible for enrollment. Results: From 1 h and continuing through 6 h postdose, the proportion of responders was significantly greater (p≤0.01) for AAC than placebo. The pain intensity difference from baseline was significantly greater (p≤0.05) for AAC than placebo from 0.5 h through 6 h. The proportion of subjects reporting improvement in functional disability, photophobia, and phonophobia was significantly greater for AAC than placebo from 2 h through 6 h postdose. Conclusions: The nonprescription combination of AAC was well tolerated and effective.

UR - http://www.scopus.com/inward/record.url?scp=0032832122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032832122&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.1999.019007684.x

DO - 10.1046/j.1468-2982.1999.019007684.x

M3 - Article

C2 - 10524663

AN - SCOPUS:0032832122

VL - 19

SP - 684

EP - 691

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -